From medicalxpress.com Researchers at Karolinska Institutet in Sweden have identified a protein that could help physicians decide what type of therapy patients with hormone driven breast cancer should go through. In a study, published in Nature Communications, they show that high levels of a protein called retinoic acid receptor alpha (RARA) in breast tumors can be linked to an insufficient …
Experimental ‘iKnife’ Tells Surgeon Whether Tissue Is Cancerous
From Drugs.com An experimental surgical “knife” can accurately identify cancerous tissue as a surgeon cuts through it, creating the potential for shorter cancer surgeries that remove all traces of tumor, according to a study co-written by the device’s developers. The “iKnife” uses electricity to cauterize surgical incisions as they are made, and then samples the resulting smoke to determine whether …
Kids Affected by A Parent’s Cancer and College Students
You have been diagnosed or know someone else who has been diagnosed with cancer and you know that your life and the lives of your family members and friends will never be the same. There is support for the grown ups but what happens to the children of a parent affected with cancer? More than likely they are left on …
New drug treats breast cancer
The Walter And Eliza Hall Institute Breast cancer researchers Dr Delphine Merino, Dr François Vaillant, Professor Geoff Lindeman, Professor Jane Visvader and colleagues have shown that BH3-mimetic anti-cancer compounds were effective in treating aggressive breast cancers when combined with a conventional chemotherapy drug. Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could …
Risk Of Breast Cancer Recurrence After Tamoxifen Treatment Predicted By Biomarker
From Medical News Today A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In their report published online in the Journal of the National Cancer Institute, Massachusetts General Hospital (MGH) Cancer Center investigators describe finding …
CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer
(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …
Independence Day Through the Eyes of a Breast Cancer Survivor
The 4th of July has always been a huge celebration in our country to commemorate our independence from England so many centuries ago. There are parades and cook outs and fireworks galore. Many people travel at this time because the kids are out of school and the holiday allows for an extra vacation day. But I can’t help but wonder …
“Miracle” Breast Cancer Drug and “Youth Hormone” Pill Steal Show at Prestigious Endocrine Society Conference
PRNewswire/ — It may seem like an odd pairing: an oral growth hormone-boosting supplement and possible cure for breast cancer. But these were two of the most talked about topics at ENDO 2013, The Endocrine Society’s 95th Annual Meeting & Expo that just convened in San Francisco. And now some are saying this focus by some of the top internal medicine …
Breakthrough in breast cancer surgery without disfigurement
Serious tissue damage and disfigurement are a major fallout of most cancer therapies, but the one for breast cancer in particular has life-altering impact on women. Chicago-based Ananda Chakrabarty, a world-renowned pioneering biotech scientist, and Washington-based Susan Finston, a veteran of the biotech industry, together believe they are potentially close to resolving this major medical challenge. Finston passionately talks about …
MD Anderson Researcher Reassesses Avastin’s Function In Treating Brain Cancer
From BioNews TX With the cancer drug Avastin on the ropes after losing FDA support for the treatment of breast cancer two years ago and an increasing chorus of criticism, an MD Anderson researcher has weighed in on where he thinks the drug’s effectiveness lies. In a recent cancer study conducted at MD Anderson for the initial treatment of glioblastoma, one …